ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ACHN Achillion Pharmaceuticals Inc

6.76
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Achillion Pharmaceuticals Inc NASDAQ:ACHN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.76 6.93 6.75 0 01:00:00

Achillion to Present at the Baird 2018 Global Healthcare Conference

30/08/2018 11:00am

GlobeNewswire Inc.


Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Achillion Pharmaceuticals Charts.

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the Baird 2018 Global Healthcare Conference on Thursday, September 6th, 2018, at 9:05 a.m. ET at the Intercontinental New York Barclay Hotel, in New York, NY.

The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in the Company’s oral factor D portfolio was discovered in its laboratories and is wholly owned. Achillion is focusing its drug development activities on alternative pathway-mediated rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase 3 and commercialization, the Company plans to work closely with key stakeholders including patients, payors, regulators and healthcare professionals.  More information is available at http://www.achillion.com.

Investors & Media:Brian DiDonatoVice President, Investor Relations and Corporate CommunicationsAchillion Pharmaceuticals, Inc.Tel. (203) 752-5452 bdidonato@achillion.com

1 Year Achillion Pharmaceuticals Chart

1 Year Achillion Pharmaceuticals Chart

1 Month Achillion Pharmaceuticals Chart

1 Month Achillion Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock